TNKS2 and hepatocellular carcinoma: To validate the therapeutic potential of targeting TNKS1 and TNKS2, we first used a RNA interference approach to knockdown TNKS1 and TNKS2 in three commonly used HCC cell lines (HepG2, Hep40, and Huh7) and examined the effects on cell proliferation.